CTOs on the Move

Oramed

www.oramed.com

 
Oramed Pharmaceuticals (Nasdaq/TASE: ORMP) is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, with offices in the United States and Israel, Oramed has developed a novel Protein Oral Delivery (POD™) technology. Oramed is seeking to transform the treatment of diabetes through its proprietary lead candidate, ORMD-0801, which is being evaluated in two pivotal Phase 3 studies and has the potential to be the first commercial oral insulin capsule for the treatment of diabetes. In addition, Oramed is developing an oral GLP-1 (Glucagon-like peptide-1) analog capsule (ORMD-0901).
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.oramed.com
  • 1185 Avenue of the Americas 3rd Floor
    New York, NY USA 10036
  • Phone: 646.844.1164

Executives

Name Title Contact Details

Funding

Oramed raised $50M on 11/03/2021

Similar Companies

Sorenson Genomics

Sorenson Genomics is a Salt Lake City, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

CDx Diagnostics

The developer of advanced diagnostic tests that empower physicians to preempt cancer, including WATS3D, for increased detection of Barrett`s esophagus and dysplasia.

Valley Oaks Health

Provectus Biopharmaceuticals

Provectus Biopharmaceuticals is investigating new therapies for the treatment of skin cancer, liver cancer and breast cancer. Provectus` investigational oncology drug, PV-10, is an ablative immunotherapy under investigation in solid tumor cancers.

Gala Therapeutics

Gala Therapeutics is a medical devices company developing therapies to improve survival, quality of life, and outcomes for patients with pulmonary diseases.